Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid (RPAH2)

Moderate Hypofractionated Radiotherapy (62 Gy in 20 Fractions of 3.1 Gy) Versus Stereotactic Radiotherapy (37.5 Gy in 5 Fractions of 7.5 Gy) With Hyaluronic Acid Injection Between the Prostate and the Rectum for Prostate Cancer of Low- to Intermediate Risk; RPAH2

The present randomized, open, multicentric Phase II trial, in parallel groups with two arms of treatment, compares the treatment A, moderate hypofractionated radiotherapy of 62Gy, to treatment B, stereotactic irradiation of 37.5 Gy with hyaluronic acid injection in the space between the prostate and the rectum to preserve the rectal-wall from high doses of irradiation. The study aims to assess the rates of late urinary toxicities of grade ≥ 2 induced by a moderate hypofractionated radiotherapy (62Gy in 20 fractions of 3.1Gy) and by a stereotactic radiotherapy (37.5Gy in 5 fractions of 7.5Gy), and the rectal toxicities after an injection of hyaluronic acid between the rectal wall and the prostate.

Ninety-six patients and 9 centers are included in the protocol.

Study Overview

• Status: Completed
• Conditions: Prostatic Adenocarcinoma
• Intervention / Treatment: Radiation: Moderate hypofractionated radiotherapy; Radiation: Stereotactic radiotherapy

• Study Type: Interventional
• Enrollment (Actual): 96
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Albi, France, 81000
    • Clinique Claude Bernard Service de radiothérapie CMCO Claude Bernard
  • Dijon, France, 21079
    • Centre Georges François Leclerc
  • Marseille, France, 13009
    • Institut Paoli Calmettes
  • Nantes, France, 44805
    • Site Hospitalier Nord Boulevard Jacques Monod
  • Pierre-Bénite, France, 69495
    • Centre Hospitalier Lyon Sud
  • St Etienne, France, 42270
    • Institut de Cancerologie de La Loire
  • Toulouse, France, 31300
    • Groupe ONCORAD Clinique Pasteur

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• age superior or equal to 18 years and inferior to 80 years.
• patient with a low- to intermediate-risk prostate cancer, according to D'Amico classification, for an exclusive irradiation.
• prostate cancer histologically proven.
• performance index OMS (World Health Organization) of grade 0-2.
• indication of external beam radiotherapy validate by the medical commission of the institution.
• IPSS (International Prostate Symptom Score < 15/35 (without alpha-blocker).
• the signed consent form.

Exclusion Criteria:

• Rectal surgery antecedents.
• prostate resection less than 6 mois.
• Involvement of the seminal vesicles or of the capsule on MRI.
• patient who can't cooperate during the treatment.
• pelvic irradiation antecedents.
• antecedents of inflammatory intestinal pathologies.
• neoplasia.
• patients treated with anti-neoplastic or anti-angiogenic or with other treatments used in rheumatology and which may include methotrexate (in order not to have a radiosensitizing effect).
• patients receiving anticoagulant treatment.
• other undergoing study that may interfere with the present study.
• patient under legal protection measure.
• hypersensitivity to hyaluronic acid.
• patient with auto-immune disease.
• patient receiving immunosuppressive medication.
• severe allergies.
• history of endocarditis.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Moderate Hypofractionated radiotherapy (62Gy); 20 fractions of 3.1Gy	Radiation: Moderate hypofractionated radiotherapy; Moderate hypofractionated radiotherapy of 62Gy in 20 fraction of 3.1Gy.
Experimental: Stereotactic radiotherapy (37.5Gy); 5 fractions of 7.5Gy)	Radiation: Stereotactic radiotherapy; Stereotactic radiotherapy of 37.5Gy in 5 fraction of 7.5Gy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients with late urinary toxicities of grade ≥ 2 after moderate hypofractionated radiotherapy (62Gy in 20 fractions of 3.1Gy) and after stereotactic radiotherapy (37.5Gy in 5 fractions of 7.5Gy).	Late urinary toxicities of grade ≥ 2 assessed using the Common Toxicity Criteria for Adverse Effects ( CTCAE) v 4.0 classification from 3 months to 3 years.	Follow-up at ≥ 3 months after the radiotherapy and up to 3 years.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Survival rates without biological relapse in both arms.	Survival rates without biological relapse (increase of the PSA (prostate-specific antigen) beyond nadir + 2 ng/ml, using Phoenix definition).	3 years.
Evaluation and comparison of the acute urinary and rectal toxicities in both arms.	all toxicities will be listed using Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0.	3 months: evaluation at 3 months.
Evaluation and comparison of the sexual preservation rates in both arms.	evaluation and comparison of the sexual preservation rates in both arms using International Index of Erectile Function (IIEF).	3 years.
Late rectal toxicities in both arms, for the evaluation of the hyaluronic acid efficacy to preserve the rectal wall in both approaches.	Late rectal toxicities in both arms, for the evaluation of the hyaluronic acid efficacy to preserve the rectal wall in both approaches, using Common Toxicity Criteria for Adverse Effects (CTCAE) 4.0.	3 years.

Collaborators and Investigators

• Sponsor: Hospices Civils de Lyon

Publications and helpful links

General Publications

• Jmour O, Benna M, Champagnol P, Ben Mrad M, Hamrouni A, Obeid L, Lahmamssi C, Bousarsar A, Vial N, Rehailia-Blanchard A, Sotton S, Lan M, Langrand-Escure J, Vallard A, Magne N. CBCT evaluation of inter- and intra-fraction motions during prostate stereotactic body radiotherapy: a technical note. Radiat Oncol. 2020 Apr 19;15(1):85. doi: 10.1186/s13014-020-01534-2.

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2015
• Primary Completion (Actual): January 1, 2020
• Study Completion (Actual): January 1, 2020

Study Registration Dates

• First Submitted: February 6, 2015
• First Submitted That Met QC Criteria: February 6, 2015
• First Posted (Estimate): February 11, 2015

Study Record Updates

• Last Update Posted (Actual): March 17, 2022
• Last Update Submitted That Met QC Criteria: March 2, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Keywords: Prostate; Hypofractionated radiotherapy; Spacer; Stereotactic irradiation; Rectal and bladder toxicities
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Carcinoma; Neoplasms, Glandular and Epithelial; Adenocarcinoma
• Other Study ID Numbers: 2014-846